| Background and Objective:Survivin is a novel inhibitor of apoptosis protein (IAP) . It's a new member of IAP family in mammalian. It mainly acts on the cross point of every path of apoptosis and suppresses caspase-3 and caspase-7 directly. As a generally used mitosis regulator, the apoptotic pathway controlled by Survivin maintains the conservation of genes together with other components of G2/M checkpoint during the process of mitosis. It was discovered that Survivin expresses highly in embryonic tissue and plays a crucial role in tissue differentiation and organ formation in embryogenesis, but it is completely down-regulated and undetectable in normal adult tissues, and prominently reexpresses in most common human cancers. Over expression of Survivin enhances cell viability and leads abnormal cells to overcome apoptotic checkpoint and to proliferate extraordinarily. Survivin and other mutant genes take part in the carcinogenesis and the development of carcinomas together. In this experiment, we researched the expression of Survivin in normal breast tissue, precancerous lesions of breast and breast carcinoma. Furthermore, the relationship between Survivin expression and P53 expression was analyzed to investigate the function of Survivin inthe carcinogenesis and the development of breast carcinoma.Method:Immunohistochemical Avidin-Biotin Complex technique was used to examine the expression of Survivin and P53 protein in 10 cases of normal breast tissue, 11 cases of simple hyperplasia (stage I ), 23 cases of atypical hyperplasia(including 11 cases of stage II and 12 cases of stage III ), and 42 cases of breast cancer tissue( including 31 cases of invasive ductal cancer, 6 cases of medullary carcinoma, 4 cases of adenocarcinoma and 1 case of Paget disease). Furthermore, their correlations with the features of clinical pathology and the relationships between Survivin expression and the expression of P53 protein were investigated.Results:1. In normal breast tissue, simple hyperplasia, atypical hyperplasia and breast cancer tissue, the histochemical score Median of Survivin protein were 0.00, 1.00, 1.00, 6.00 respectively. There was no significant difference between the normal breast tissue group and the simple hyperplasia group (P>0.05). The difference was significant when normal breast tissue group was compared with atypical hyperplasia group and breast cancer group (P<0.001), and when atypical hyperplasia was compared with breast cancer group (P<0.01). The positive rate of Survivin in breast cancer was significantly higher than those in other groups (P<0.001), and the positive rate of Survivin in atypical hyperplasia was significantly higher than that in normal and simple hyperplasia groups too (P<0.05).2. In normal breast tissue, simple hyperplasia, atypical hyperplasia and breast cancer tissue, the positive rates of P53 protein were 0.00%, 0.00%, 17.39%(4/23), 40 .48%( 17/42) respectively. The positive rates in hyperplasia and breast cancer were significantly higher than those in normal breast tissue and simple hyperplasia group (P<0.05). The positive rate in breast cancer group was higher than that in atypical hyperplasia but there was no significant difference between them (P>0.05).3. In the 42 cases of breast cancer, the histochemical score Median of Survivin in invasive ductal cancer tissue and other types of breast cancer were 6.00, 4.00, respectively. There was no significant difference between them (P>0.05). The positive rates of Survivin and P53 protein in them were not significantly different (P>0.05).4. In the 42 cases of breast cancer, the histochemical score of Survivin in clinical stage III -IV was higher than that in stage I -II, but there was no significant difference between them (P>0.05), It was same to the positive rates of Survivin and P53 protein (P>0.05).5. In the 42 cases of breast cancer, the histochemical score of Survivin in the group with lymph node metastasis was not significantly different with the group without lymph node metastasis (P>0. |
PDF Full Text Request